Preclinical efficacy of daratumumab in T-cell acute lymphoblastic leukemia

As a consequence of acquired or intrinsic disease resistance, the prognosis for patients with relapsed or refractory T-cell acute lymphoblastic leukemia (T-ALL) is dismal. Novel, less toxic drugs are clearly needed. One of the most promising emerging therapeutic strategies for cancer treatment is ta...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Blood
Autores principales: Bride, Karen L., Vincent, Tiffaney L., Im, Soo-Yeon, Aplenc, Richard, Barrett, David M., Carroll, William L., Carson, Robin, Dai, Yunfeng, Devidas, Meenakshi, Dunsmore, Kimberly P., Fuller, Tori, Glisovic-Aplenc, Tina, Horton, Terzah M., Hunger, Stephen P., Loh, Mignon L., Maude, Shannon L., Raetz, Elizabeth A., Winter, Stuart S., Grupp, Stephan A., Hermiston, Michelle L., Wood, Brent L., Teachey, David T.
Formato: Artigo
Lenguaje:Inglês
Publicado: American Society of Hematology 2018
Materias:
Lymphoid Neoplasia
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC5833263/
https://ncbi.nlm.nih.gov/pubmed/29305553
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2017-07-794214
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares